

Conclusions

- **A combined 3-biomarker HRD score is a superior predictor of survival of platinum treated ovarian cancer patients than any of the individual biomarker components (LOH, TAI, LST).**
- **HRD score in combination with *BRCA1/2* mutation status is currently being evaluated as a predictor of response to platinum and PARP inhibitors in multiple prospective clinical studies.**